Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
;
Ansar A Pathan;
Tamara K Berthoud;
Susanna J Dunachie;
Kathryn T Whelan;
Nicola C Alder;
Clare R Sander;
Adrian VS Hill;
Helen McShane;
(2008)
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
Vaccine, 26 (41).
pp. 5269-5275.
ISSN 0264-410X
DOI: 10.1016/j.vaccine.2008.07.040
In clinical trials recombinant-modified vaccinia virus Ankara expressing the Mycobacterium tuberculosis antigen 85A (MVA85A) induces approximately 10 times more effector T cells than any other recombinant MVA vaccine. We have found that in BCG primed subjects MVA85A vaccination reduces transforming growth factor beta 1 (TGF-beta1) mRNA in peripheral blood lymphocytes and reduces TGF-beta1 protein in the serum, but increases IFN-gamma ELISPOT responses to the recall antigen SK/SD. TGF-beta1 is essential for the generation of regulatory T cells and we see a correlation across vaccinees between CD4+CD25hiFoxP3+ cells and TGF-beta1 serum levels. This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines.
-
picture_as_pdf - 1-s2.0-S0264410X08009845-main.pdf
-
subject - Published Version
-
- Available under Creative Commons: 3.0